[Cyclosporine-induced graft-versus-host disease in a syngeneic bone marrow transplantation].
A 33-year-old woman with AML (M4) resistant to chemotherapy received syngeneic marrow graft from her identical twin following high dose busulfan and etoposide. However, the relapse was confirmed on the 60th day after the procedure. Since she failed to achieve remission despite intensive chemotherapy, a second BMT from the same donor was performed following total body irradiation and high dose etoposide on the 126th day after the initial BMT. At this time, cyclosporine (1 mg/kg/day) was administered to induce graft-versus-host disease (GVHD). Skin rash appeared on the 18th day after the 2nd BMT, and biopsy from the rash on the 23rd day showed a typical picture of cutaneous GVHD (grade 2) and there was no evidence of viral infection. On the 36th day after the 2nd BMT, the patient died of veno-occlusive disease. Although graft-versus-leukemia effect in this patient could not be evaluated because of early death, the induction of GVHD with cyclosporine might be effective to reduce the relapse rate after syngeneic or autologous BMT. Further studies are required to confirm this effect.
Hashimoto
S
S
Devivion of Blood Transfusion, Chiba University Hospital.
Kawano
E
E
Hirasawa
A
A
Morio
S
S
Aotuka
N
N
Nakamura
H
H
Oh
H
H
Asai
T
T
Yoshida
S
S
Ishii
G
G
D000328:Adult; D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D015479:Leukemia, Myelomonocytic, Acute / Q000628:therapy
D016572:Cyclosporine